The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
 
Howard Kaufman
Consulting or Advisory Role - Alkermes; Amgen; Merck; Merck Serono; Prometheus
Research Funding - Bristol-Myers Squibb/Medarex
 
Jiafeng Wang
No Relationships to Disclose
 
Brendan D. Curti
Honoraria - Prometheus
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Agonox; Prometheus
 
Joseph Clark
No Relationships to Disclose
 
Marc S. Ernstoff
No Relationships to Disclose
 
Ann Silk
No Relationships to Disclose
 
Janice M. Mehnert
Consulting or Advisory Role - Amgen/Dompé (Inst)
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Other Relationship - Amgen
 
Andrew Zloza
No Relationships to Disclose
 
Joe Shih
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Research Funding - Prometheus